InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
61,474.64
(
0.96%
)
Post# of 252431
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

floblu14

Send PM Follow Ignore
Followers 22
Posts 3666
Boards Moderated 0
Alias Born 07/20/2006

floblu14

Re: DewDiligence post# 234423

Friday, 08/28/2020 5:40:05 AM

Friday, August 28, 2020 5:40:05 AM

Post# of 252431
Dew - right on!

28 August:

Enanta resumed with a Buy at Roth Capital 16:19 ENTA Roth Capital analyst Zegbeh Jallah resumed coverage of Enanta Pharmaceuticals with a Buy rating and $104 price target. The current stock price is largely reflective of the company's hepatitis C virus revenue stream and its cash position of $435M, thus leaving its clinical pipeline of potential blockbusters undervalued, Jallah tells investors in a research note. Enanta has a "very potent" hepatitis B virus core inhibitor, EDP-514, in Phase 2 studies with data expected in the first half of 2021, notes the analyst.

Read more at:
https://thefly.com/n.php?id=3152704
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up